David Meder
Papers
1
Total Citations
24
H-Index
1
About
David Meder is a leading clinical neuroscientist whose research focuses on the neural mechanisms underlying movement disorders, particularly Parkinson’s disease. His most cited work demonstrates a groundbreaking contribution to the treatment of levodopa-induced dyskinesia (LID), a debilitating side effect of long-term dopamine therapy. In a pivotal 2020 randomized cross-over trial, Meder showed that low-frequency transcranial stimulation of the pre-supplementary motor area (pre-SMA) can significantly alleviate LID in Parkinson’s patients. This finding, supported by pharmacodynamic functional MRI evidence, directly targets the excessive pre-SMA activation triggered by levodopa, offering a non-invasive therapeutic avenue for a condition that affects millions worldwide. With 24 citations, this study has already influenced clinical approaches to managing Parkinson’s motor complications. Meder’s work bridges advanced neuroimaging and neuromodulation, providing mechanistic insights into basal ganglia-cortical loops. His research not only deepens our understanding of dyskinesia pathophysiology but also paves the way for personalized, circuit-based interventions. For students and researchers, Meder exemplifies how translational neuroscience can transform patient care, combining rigorous experimental design with real-world clinical impact.
Research Focus
Key Achievements
Top Papers
- 1